- Home
- GNTA vs CVM Comparison
GNTA vs CVM Comparison
Compare GNTA & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | CVM |
|---|---|---|
| Founded | 2014 | 1983 |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.8M | 30.6M |
| IPO Year | 2021 | 1996 |
Fundamental Metrics
Financial Performance| Metric | GNTA | CVM |
|---|---|---|
| Price | $0.63 | $1.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.50 |
| AVG Volume (30 Days) | 54.0K | ★ 262.8K |
| Earning Date | 03-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $0.55 | $0.89 |
| 52 Week High | $10.00 | $9.35 |
Technical Indicators
Market Signals| Indicator | GNTA | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 44.56 |
| Support Level | $0.59 | $1.01 |
| Resistance Level | $0.68 | $1.68 |
| Average True Range (ATR) | 0.06 | 0.28 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 24.75 | 0.85 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is an industrial consolidator focused on acquiring majority or full ownership of privately held, established companies operating in Italian national-security-regulated sectors. Its acquisition activities span aerospace, defense, national security (including cybersecurity), and biotechnology/biosecurity, with a focus on businesses covered by Italy's Golden Power legislation.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.